Here are 1-3 brief analogies for 20/20 Biolabs (AIDX):

• Quest Diagnostics for AI-powered multi-cancer early detection blood tests.

• AWS for diagnostics lab services.

• OneTest for Cancer: An AI-powered, laboratory-based blood test for multi-cancer early detection, also licensed to overseas labs.
• BioCheck: A field test kit designed for screening suspicious powders for bioterror agents.
• Clinical Laboratory Innovation Accelerator (CLIAx): A shared CLIA laboratory service enabling overseas diagnostics start-ups to launch novel lab tests in the U.S.
• OneTest for Longevity: An upcoming blood test, expected to launch in H1 2026, which measures inflammatory biomarkers for chronic disease prevention.

• Individuals (Patients) through Healthcare Providers: As the primary source of revenue, the company's OneTest for Cancer (and the upcoming OneTest for Longevity) are described as "lab tests in the U.S." These tests are typically ordered by healthcare providers for individual patients for early detection and prevention of cancers and chronic diseases.
• Overseas Diagnostic Laboratories and Start-ups: This category encompasses two distinct groups: (i) overseas laboratories that license 20/20 Biolabs' algorithms for the OneTest for Cancer, and (ii) overseas diagnostics start-ups that utilize 20/20 Biolabs' CLIAx (Clinical Laboratory Innovation Accelerator) facility to launch novel lab tests in the U.S.
• Government/Public Safety Organizations: Customers for the BioCheck field test kit, used for screening suspicious powders for bioterror agents, would typically include government agencies, law enforcement, first responders, and other public safety or security-focused organizations.

Jonathan Cohen, President & CEO

Mr. Cohen is the founder of 20/20 BioLabs and has served as its Chief Executive Officer, President, and a director since August 2000. He is a co-inventor of the company's OneTest and BioCheck products and has overseen their commercial launch and sales. He has also led significant license, research, technology transfer, investment, and sales and marketing agreements with major corporations such as Eastman Kodak, Abbott Diagnostics, Johnson & Johnson, IBM, and Ping An. Before founding 20/20 BioLabs, Mr. Cohen served as patent and general counsel for Ventana Medical Systems Inc. and Oncor Inc.

Alan B. Bergman, Interim Chief Financial Officer

Mr. Bergman has served as Interim Chief Financial Officer since December 2025, with his appointment as Chief Financial Officer effective upon the registration statement's effectiveness. His prior roles include Chief Financial Officer of Plethy, Inc., a private musculoskeletal med-tech company, from December 2024 to December 2025, and Chief Financial Officer of Smart for Life, Inc., a publicly traded company, from January 2021 to December 2024. He also held CFO and VP Finance positions at Bright Mountain Media, Inc. and Greenlane Holdings, Inc., respectively. Mr. Bergman started his career as a senior auditor with Deloitte in 2000 and has held audit management roles at other firms. He earned his Master's Degree in Accounting from the University of Miami.

Jiming Zhou, Ph.D., Chief Operating Officer

Dr. Zhou possesses over 20 years of experience in the healthcare and biotech industries. He co-founded Firefox Pharmaceuticals and Fairfax Medical Consulting. His academic career began as an associate professor at Sichuan University, followed by extensive research at the University of Iowa. In 2005, he transitioned to industrial R&D, where he managed multiple clinical laboratories and led significant pharmaceutical projects.

Michael Lebowitz, Ph.D., Chief Scientific Officer

Dr. Lebowitz has been the Chief Scientific Officer since January 2020, having previously served as Director of Research & Development from 2009 to 2012. He also holds the position of CSO at Athanor Biosciences. With over 30 years of research experience, including 22 years in industry, Dr. Lebowitz has been instrumental in launching six laboratory-developed tests and establishing two CLIA-certified laboratories. He holds a Ph.D. from Johns Hopkins University School of Medicine and is an adjunct faculty member there and at the University of Maryland, Baltimore County.

Ron Baker, Chief Business Officer

Mr. Baker brings extensive experience in clinical research, operations, technical sales, marketing, and business development within oncology laboratory services. Before joining 20/20 BioLabs, he held executive positions at Roche Diagnostics, Roche Clinical Labs, and SGS Life Sciences. He obtained his B.S. in Biology from Loyola University.

Key Risks for 20/20 Biolabs (AIDX)

1. Concentration of Revenue in OneTest for Cancer: The company is heavily reliant on its OneTest for Cancer product, which accounted for approximately 87% of its revenues for the nine months ended September 30, 2025 and 2024, and 85% for the year ended December 31, 2024. Any significant challenges related to this product, such as regulatory hurdles, market acceptance, competition, reimbursement issues, or efficacy concerns, could severely impact the company's overall financial performance.
2. Regulatory and Commercial Challenges in AI-Powered Diagnostics: As a developer of AI-powered, laboratory-based blood tests for early detection of cancers and chronic diseases, 20/20 Biolabs faces significant risks associated with regulatory approval processes (e.g., maintaining CLIA license and CAP accreditation), clinical validation, market adoption by healthcare providers, and securing favorable reimbursement policies from insurers. The successful launch and commercialization of new products, such as OneTest for Longevity, also depend on navigating these complex challenges.
3. Rapid Technological Change and Competition: The field of AI-powered diagnostics for early disease detection is highly dynamic and competitive. 20/20 Biolabs operates in an environment where new technologies and diagnostic methods are continuously emerging. There is a risk that competitors could develop superior or more cost-effective solutions, or that the company's current AI algorithms and testing methodologies could become technologically obsolete, potentially eroding its market position.

For 20/20 Biolabs (AIDX), the addressable markets for its main products and services are as follows:

• OneTest for Cancer (Multi-Cancer Early Detection, or MCED, blood test):
  • The global multi-cancer early detection (MCED) test market was valued at approximately USD 1.5 billion in 2024 and is projected to reach USD 5.8 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 14.1% from 2025 to 2034.
  • The U.S. multi-cancer early detection market is expected to reach a projected revenue of US$ 845.6 million by 2030, with a CAGR of 17% from 2025 to 2030.
• OneTest for Longevity (inflammatory biomarkers test):
  • The global inflammatory marker market was valued at approximately USD 5.3 billion in 2023 and is expected to reach USD 9.2 billion by 2032, growing at a CAGR of 6.1%.
  • The U.S. inflammation test kit market is projected to be valued at USD 1.1 billion in 2024 and is expected to reach USD 1.9 billion by 2033, demonstrating a CAGR of 6.1%.
• BioCheck (field test kit for screening suspicious powders for bioterror agents):
  • The global bioterrorism detection market was valued at USD 6.72 billion in 2023 and is expected to reach nearly USD 9.71 billion by 2030, growing at a CAGR of 5.4% from 2024 to 2030.
  • The U.S. bio-detection market was valued at $4.8 billion in 2024.
• CLIAx (Clinical Laboratory Innovation Accelerator, a shared CLIA laboratory for overseas diagnostics start-ups):
  • While a specific market size for shared CLIA laboratories for start-ups is not available, the broader U.S. clinical laboratory services market, which provides the regulatory and operational framework, generated $99.7 billion of revenue in 2024 and is projected to reach $122.5 billion by 2029, growing at a 4.2% CAGR.

Expected Drivers of Future Revenue Growth for 20/20 Biolabs (AIDX)

Over the next 2-3 years, 20/20 Biolabs (AIDX) is expected to drive revenue growth through several key initiatives:

1. Increased Adoption and Sales of OneTest for Cancer: As the primary commercial focus and largest revenue generator, the continued expansion of sales and adoption of the AI-powered, multi-cancer early detection (MCED) blood test, OneTest for Cancer, is anticipated to be a significant driver of revenue growth.
2. Successful Launch and Commercialization of OneTest for Longevity: The company expects to launch OneTest for Longevity, which measures inflammatory biomarkers, in the first half of 2026. This new product family represents an entirely new revenue stream and its successful market penetration and growth will be a crucial driver.
3. Expansion of the Clinical Laboratory Innovation Accelerator (CLIAx) Program: Revenue from the CLIAx, which offers shared CLIA laboratory services for overseas diagnostics start-ups, is expected to grow as more international companies utilize this platform to launch novel lab tests in the U.S.
4. Geographic Expansion and Increased Licensing of OneTest for Cancer Algorithms: Beyond direct lab testing in the U.S., 20/20 Biolabs licenses its OneTest for Cancer algorithms to overseas labs. Expanding these licensing agreements to new international partners is a potential avenue for future revenue growth.

Share Issuance

• 20/20 Biolabs registered up to 15,130,055 shares of common stock for resale by existing stockholders in connection with its direct listing on Nasdaq in February 2026.
• The company offered convertible notes in July 2025 with a maximum raise amount of $700,000, convertible into equity.
• Series A and Series A-2 preferred shares automatically converted into common stock upon the company's Nasdaq listing in February 2026.

Inbound Investments

• Upon its Nasdaq debut in February 2026, 20/20 Biolabs secured a contingent financing agreement with an institutional investor for up to $40 million, with the initial $5 million expected to close on the listing day.
• In July 2025, the company offered convertible notes to investors with a maximum raise amount of $700,000.

Capital Expenditures

• Capital expenditures were ($0.3 million) in 2022 and ($0.2 million) in 2023.
• The company's latest annual financial reports show $889.05K in Property, Plant & Equipment (Net).
• Capital expenditures are primarily focused on maintaining and enhancing its CAP-accredited, CLIA-licensed laboratory in Gaithersburg, MD, where its OneTest brand blood tests are run and its Clinical Laboratory Innovation Accelerator (CLIAx) is hosted.